Literature DB >> 24659653

Does treatment interruption and baseline hemoglobin affect overall survival in early laryngeal cancer treated with radical radiotherapy? 10 years follow up.

Hany Eldeeb1, Seham Abdel-Khalk.   

Abstract

PURPOSE: In this retrospective study we assessed different factors affecting the outcome of early laryngeal cancer, focusing on the impact of the pretreatment hemoglobin (Hb) level, time interval between diagnosis and start of radiotherapy, as well as treatment interruption during the course of radiotherapy.
METHODS: We reviewed the hospital records, oncology database and radiotherapy treatment sheets of 88 patients with T1-T3 N0M0 squamous cell carcinoma of the larynx who had been treated with radical radiotherapy at Northamptonshire Centre for Oncology during the period from 1st January 1996 till 31st December 2002 inclusive. Patients were followed up for 10 years.
RESULTS: There were no significant overall survival differences with regard to sex , stage, radiotherapy dose received, treatment interruption for 1 to 2 days , as well as the delay to start radiotherapy (mean delay 57 days). However, there was statistically significant adverse overall survival outcome with increasing age (p<0.001). On the other hand, patients with pretreatment Hb level >12 g/dl had significant statistical overall survival benefit over those with ≤12 g/dl (p=0.018).
CONCLUSION: Pretreatment Hb level had a significant impact on overall survival in patients with early laryngeal carcinoma treated with radical radiotherapy. Time to start radiation treatment, treatment interruption for 1 or 2 days and different dose / fractionations did not affect the overall survival.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659653

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  2 in total

1.  Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization.

Authors:  Zhi-Huan Lin; Xing Li; Ying-Fen Hong; Xiao-Kun Ma; Dong-Hao Wu; MingSheng Huang; Zhan-Hong Chen; Jie Chen; Min Dong; Li Wei; Tian-Tian Wang; Dan-Yun Ruan; Ze-Xiao Lin; Xiang Zhong; Yan-Fang Xing; Jing-Yun Wen; Xiang-Yuan Wu; Qu Lin
Journal:  Tumour Biol       Date:  2015-09-28

2.  Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates.

Authors:  Tanja Eichkorn; Farastuk Bozorgmehr; Sebastian Regnery; Lisa A Dinges; Andreas Kudak; Nina Bougatf; Dorothea Weber; Petros Christopoulos; Thomas Muley; Sonja Kobinger; Laila König; Juliane Hörner-Rieber; Sebastian Adeberg; Claus Peter Heussel; Michael Thomas; Jürgen Debus; Rami A El Shafie
Journal:  Front Oncol       Date:  2020-12-01       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.